Medtronic vs Stryker
MDT and SYK side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How MDT and SYK compare
Medtronic and Stryker are about the same size, with market caps of $123B and $112B.
On earnings, Medtronic is cheaper: it trades at 23.7× trailing earnings, against 31.1× for Stryker.
Medtronic grew revenue faster over the last twelve months (9.8% versus 7.9% for Stryker).
Medtronic keeps more of each dollar of sales as profit, with a net margin of 13.9% compared with 13.8% at Stryker.
Both pay dividends: Medtronic yields 3.0% and Stryker 1.2%.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | MDT | SYK |
|---|---|---|
| Size and price | ||
| Market cap | $123B | $112B |
| Share price | $96.54 | $291.86 |
| Change, 1 year | 5.2% | −21.0% |
| Change, 5 years | −21.5% | 5.7% |
| Beta (5Y) | 0.52 | 0.85 |
| Employees | 95K | 56K |
| StockData Score | ||
| Total score | 19 | 19 |
| Valuation score | 5 (better) | 4 |
| Growth score | 2 | 5 (better) |
| Performance score | 4 (better) | 3 |
| Health score | 4 | 4 |
| Dividend score | 4 (better) | 3 |
| Valuation | ||
| P/E | 23.7× (better) | 31.1× |
| P/S | 3.3× (better) | 4.3× |
| P/B | 2.5× | – |
| EV/EBITDA | 14.7× (better) | 17.5× |
| P/FCF | 20.1× (better) | 24.5× |
| PEG | 2.43 (better) | 2.87 |
| FCF yield | 5.0% (better) | 4.1% |
| Fair value | $99.74 | $381.63 |
| Margin of safety | 3.2% | 23.5% (better) |
| Growth | ||
| Revenue growth (TTM) | 9.8% (better) | 7.9% |
| Revenue growth, 5Y average | 3.8% | 11.8% (better) |
| Net income growth (TTM) | 12.3% | 23.1% (better) |
| EPS growth (TTM) | 12.1% | 23.4% (better) |
| EPS growth, 5Y average | 7.0% | 14.9% (better) |
| Profitability | ||
| Gross margin | 65.0% | 65.3% (better) |
| Operating margin | 18.1% | 20.7% (better) |
| Net margin | 13.9% (better) | 13.8% |
| FCF margin | 16.3% | 17.4% (better) |
| Return on equity | 10.7% | – |
| Return on invested capital | 7.9% | – |
| Financial health | ||
| Debt / equity | 0.56 | – |
| Net debt / EBITDA | 1.99 | 1.65 (better) |
| Interest coverage | 9.4× (better) | 9.3× |
| Current ratio | 2.07 | 2.18 (better) |
| Altman Z-score | 3.05 | 4.58 (better) |
| Piotroski F-score | 7 (better) | 5 |
| Dividends and buybacks | ||
| Dividend yield | 3.0% (better) | 1.2% |
| Payout ratio | 69.8% | 36.8% |
| Years of dividend growth | 13 | – |
| Dividend growth, 5Y average | 4.1% | – |
| Buyback yield | 0.95% | – |
| Shareholder yield | 3.9% (better) | 1.2% |
| Ownership | ||
| Held by institutions | 86.5% | 80.2% |
| Held by insiders | 0.10% | 4.1% |
| Insider net buying, 12 months | −$8.9M (better) | −$586M |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 3.1% | 1.6% |
Go deeper
- MDT stock overview
- MDT income statement
- MDT valuation and score
- SYK stock overview
- SYK income statement
- SYK valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.